Dr.Β WilliamΒ Dahut
MD, ABIM Board Certified in Internal Medicine, Hematology & Medical Oncology
Chief Scientific Officer, American Cancer Society
corporate_fareAmerican Cancer Society | Walter Reed NMMC, USA
William Dahut
MD, ABIM Board Certified in Internal Medicine, Hematology & Medical Oncology
Dr. William L. Dahut, MD, is a physician-scientist and the Chief Scientific Officer at the American Cancer Society (ACS), where he oversees strategic direction of intramural and extramural cancer research and manages more than $400 million in research funding. He continues clinical practice in the prostate cancer clinic at Walter Reed National Medical Military Center in Bethesda, Maryland. With over 40 years of clinical and research experience, Dr. Dahut is recognised as one of the most influential oncologists in genitourinary cancer.
Dr. Dahut spent the majority of his career at the National Cancer Institute, where he served in multiple senior leadership roles including Clinical Director, Deputy Director, and Scientific Director for Clinical Research at NCI's Centre for Cancer Research. Before joining ACS in 2022, he led the revitalisation of NCI's clinical research programme, growing the number of senior and physician-scientist investigators and expanding regulatory support for cell therapies. His research has focused on developing novel therapeutic strategies for adenocarcinoma of the prostate, including pioneering work combining immunotherapy, angiogenesis inhibitors, and androgen blockade. He has authored nearly 250 peer-reviewed publications with over 23,679 citations and an h-index of 78, and has trained dozens of medical oncology fellows throughout his career. Dr. Dahut is Professor of Medicine at the Uniformed Services University of the Health Sciences and served as Chair of the Department of Defense Prostate Cancer FY24 Programmatic Panel.
CancerFax can coordinate structured medical-report review and second-opinion support for international patients seeking expert input from a physician of Dr. Dahut's calibre, subject to case review and availability.
Why Seek a Second Opinion from Dr. William Dahut?
Dr. Dahut is among the most cited researchers in genitourinary oncology, with four decades of clinical trial leadership and prostate cancer expertise at the highest level of US cancer research.
Areas of Specialisation
Genitourinary oncology with a deep focus on prostate cancer, clinical trial design, and combination immunotherapy strategies
Dr. Dahut's clinical and research expertise centres on prostate cancer across all stages, including metastatic castration-resistant prostate cancer, with additional expertise in bladder cancer, kidney cancer, and other genitourinary and gynaecologic malignancies.
Prostate Cancer β All Stages
Comprehensive management of prostate cancer including hormone-sensitive, castration-resistant, and metastatic disease.
- arrow_rightNovel therapeutic strategy development including immunotherapy and AR pathway inhibition
- arrow_rightAvelumab and other anti-PD-L1 monoclonal antibody protocols
- arrow_rightCombination androgen blockade with experimental agents
- arrow_rightPrecision genomic and germline testing to guide treatment selection
- arrow_rightAndrogen deprivation therapy combined with novel systemic agents
- arrow_rightThalidomide and angiogenesis inhibitor-based regimens
- arrow_rightIntegration of radiotherapy with systemic treatment
Immunotherapy & Combination Approaches
Dr. Dahut has spent his career developing and testing combination regimens that integrate immunotherapy with standard oncology modalities.
- arrow_rightPD-1 and PD-L1 inhibitor protocols for genitourinary malignancies
- arrow_rightCombination immunotherapy with chemotherapy and androgen blockade
- arrow_rightImmunologic response assessment and biomarker-guided selection
- arrow_rightAngiogenesis inhibitors combined with standard chemotherapy regimens
- arrow_right2-Methoxyestradiol (2-ME) and related experimental approaches in advanced solid tumours
Genitourinary & Gynaecologic Oncology
Expertise extending beyond prostate cancer to a broader range of genitourinary and gynaecologic malignancies.
- arrow_rightSystemic treatment planning for advanced and metastatic bladder cancer
- arrow_rightImmunotherapy-based approaches for eligible patients
- arrow_rightTargeted and immunotherapy-based regimens for advanced renal cell carcinoma
- arrow_rightMultidisciplinary treatment planning with surgical and radiation teams
Clinical Services & Treatment Approaches
Dr. Dahut's clinical practice at Walter Reed National Medical Military Center encompasses the full range of systemic oncology for prostate and genitourinary cancers
Dr. Dahut offers comprehensive systemic treatment, precision oncology evaluation, immunotherapy, and clinical trial enrolment for patients with prostate, bladder, kidney, and related cancers. Second-opinion consultations are a core part of his practice.
Prostate Cancer Systemic Treatment
Medical OncologyFull systemic treatment planning and delivery for hormone-sensitive and castration-resistant prostate cancer.
Immunotherapy for GU Cancers
Targeted TherapyCheckpoint inhibitor and combination immunotherapy protocols for prostate, bladder, and kidney cancers.
Precision Oncology & Genomic Evaluation
DiagnosisGenomic and germline testing to guide treatment selection in prostate and other GU cancers.
Clinical Trial Enrolment
MultidisciplinaryAccess to Phase I, II, and III clinical trials in prostate and genitourinary cancers through an investigator with decades of trial leadership.
Second Opinion Consultations
Second OpinionIndependent expert review of prostate or genitourinary cancer diagnosis, pathology, and treatment plans.
Research & Publications
Nearly 250 peer-reviewed publications with 23,679+ citations and an h-index of 78
Dr. Dahut is one of the most published and cited researchers in genitourinary oncology. His work spans novel immunotherapy regimens, angiogenesis inhibition, androgen deprivation strategies, and landmark Phase IβIII clinical trials in prostate and GU cancers.
Dr. Dahut's clinical practice is directly informed by his decades of investigational work. Patients seen at Walter Reed may have access to novel prostate cancer treatment approaches grounded in his research programme.
Education & Training
Dr. Dahut completed his medical training at Georgetown University and the National Naval Medical Center, followed by specialist fellowship training in haematology and medical oncology at the Bethesda Naval Hospital and the NCI Medicine Branch.
Clinical Experience
Dr. Dahut's career spans more than four decades, primarily at the National Cancer Institute where he rose to become Scientific Director for Clinical Research. Since 2022 he serves as Chief Scientific Officer at the American Cancer Society, overseeing more than $400 million in annual research funding.
Languages & International
Dr. Dahut conducts consultations in English.
CancerFax coordinates professional medical interpreter support for international patients where required.
CancerFax can coordinate certified medical interpreter support for international patients requiring consultations in other languages.
How CancerFax Helps You Access Dr. William Dahut
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. William Dahut's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. William Dahut's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. William Dahut before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. William Dahut's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. William Dahut's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. William Dahut's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. William Dahut
Dr. Dahut specialises in prostate cancer across all stages, including hormone-sensitive and metastatic castration-resistant prostate cancer (mCRPC), as well as bladder cancer, kidney cancer, and other genitourinary malignancies. His primary research and clinical focus has been developing novel therapeutic strategies for adenocarcinoma of the prostate.
Dr. Dahut has over 40 years of clinical and research experience in medical oncology since completing his training in 1985. He has spent the majority of his career at the National Cancer Institute in Bethesda, Maryland, and now serves as Chief Scientific Officer at the American Cancer Society.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, biopsy results, imaging (bone scan, PSMA PET, CT, or MRI), genomic profiling, and treatment history. CancerFax will review the case and coordinate the appropriate next steps. The final consultation format and availability depend on the doctor's schedule and eligibility criteria at Walter Reed National Medical Military Center.
Submit your medical reports through CancerFax using the 'Send Your Reports' button. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the next steps. Note that Dr. Dahut primarily sees patients at Walter Reed National Medical Military Center, and eligibility criteria may apply.
CancerFax can assist international patients in exploring second-opinion or consultation options with physicians of Dr. Dahut's expertise. Clinical access at Walter Reed National Medical Military Center is subject to institutional eligibility criteria. CancerFax will assess your case and advise on the most appropriate pathway.
Dr. Dahut has led and participated in Phase I, II, and III clinical trials in prostate and genitourinary cancers throughout his career at NCI. His treatment approaches include immunotherapy (anti-PD-L1 agents such as avelumab), androgen deprivation therapy, AR pathway inhibitors, angiogenesis inhibitors, and chemotherapy. Patients seen at Walter Reed may have access to investigational agents as part of active trial protocols.
Connect with William Dahut Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.